Cagrilintide + Semaglutide
Peptide therapy: benefits, side effects, cost and protocols
CagriSema is a combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) being developed by Novo Nordisk. The dual mechanism targets both amylin and GLP-1 pathways for potentially greater weight loss than either agent alone.
Sources: FDA / PubMed / ClinicalTrials.gov View
Spec sheet
- FDA status
- Research Only Not currently approved for human use in the US. Available as a research compound. Not eligible for compounding.
- Evidence
- Strong Evidence
Who it's for
Who Cagrilintide + Semaglutide is usually considered for
- Enhanced weight management
- Dual mechanism approach
- Appetite control
Mechanism
How Cagrilintide + Semaglutide works
Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.
Evidence
Key studies
85 papers on PubMed / 54 human trials
- 01
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
- 02
Garvey WT, Blüher M, Osorto Contreras CK et al
N Engl J Med / Phase 3
Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo.
- 03
Cagrilintide-semaglutide reduced body weight by 20.4% vs 3.0% with placebo
- 04
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
- 05
Davies MJ, Bajaj HS, Broholm C et al
N Engl J Med / Phase 3
Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes.
- 06
Cagrilintide-semaglutide reduced body weight by 13.7% vs 3.4% with placebo in type 2 diabetes
- 07
Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials
- 08
El-Sheikh M, Sillassen CDB, Wisborg FD et al
BMJ Open
- 09
Protocol for systematic review of cardiovascular effects of incretin-based drugs in heart failure patients
- 10
Incretin-based therapies for the treatment of obesity-related diseases
FAQ
Cagrilintide + Semaglutide questions
What is CAGRILINTIDE + SEMAGLUTIDE?
A dual-action combination of Cagrilintide (amylin analog) and Semaglutide (GLP-1 agonist) being researched for enhanced weight management effects through complementary mechanisms.
How does CAGRILINTIDE + SEMAGLUTIDE work?
Combines amylin-mediated satiety and gastric effects with GLP-1 receptor activation for dual metabolic pathway targeting.
Is CAGRILINTIDE + SEMAGLUTIDE legal to buy?
CAGRILINTIDE + SEMAGLUTIDE is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy CAGRILINTIDE + SEMAGLUTIDE?
CAGRILINTIDE + SEMAGLUTIDE is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does CAGRILINTIDE + SEMAGLUTIDE belong to?
CAGRILINTIDE + SEMAGLUTIDE is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.
What are the research benefits of CAGRILINTIDE + SEMAGLUTIDE?
CAGRILINTIDE + SEMAGLUTIDE has been studied for: Enhanced weight management, Dual mechanism approach, Appetite control. Dual-action blend targeting multiple metabolic pathways.
News
Cagrilintide + Semaglutide in the news
Co-formulation of Semaglutide and Cagrilintide Shows Promise Against Diabetes and Obesity - Pharmacy Times
Pharmacy Times / 24 months ago
Significant body weight reduction with cagrilintide-semaglutide therapy - 2 Minute Medicine
2 Minute Medicine / 15 months ago
REDEFINE 1 Trial Finds Cagrilintide–Semaglutide Combo Delivers Over 20% Weight Loss in Majority of Patients - Applied Clinical Trials Online
Applied Clinical Trials Online / 16 months ago
CagriSema for Weight Loss: How Does It Compare to Other GLP-1s? - GoodRx
GoodRx / 17 months ago
Cagrilintide and semaglutide together drive record weight loss in global trial - News-Medical
News-Medical / 17 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Considering Cagrilintide + Semaglutide?
The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.